These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10552092)

  • 1. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
    Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
    Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
    Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu M; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
    Eur J Nucl Med; 1998 May; 25(5):531-4. PubMed ID: 9575250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
    Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
    Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
    Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
    Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
    Ziebell M
    Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
    Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S
    J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; Stoof JC; Wolters EC; Van Royen EA
    Eur J Nucl Med; 1997 Sep; 24(9):1171-4. PubMed ID: 9283113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
    Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
    Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion.
    Pinborg LH; Ziebell M; Frøkjaer VG; de Nijs R; Svarer C; Haugbøl S; Yndgaard S; Knudsen GM
    J Nucl Med; 2005 Jul; 46(7):1119-27. PubMed ID: 16000280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers.
    Lavalaye J; Booij J; Reneman L; Habraken JB; van Royen EA
    Eur J Nucl Med; 2000 Jul; 27(7):867-9. PubMed ID: 10952500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain.
    Madras BK; Gracz LM; Meltzer PC; Liang AY; Elmaleh DR; Kaufman MJ; Fischman AJ
    Synapse; 1998 Jun; 29(2):105-15. PubMed ID: 9593101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.
    Pinborg LH; Videbaek C; Svarer C; Yndgaard S; Paulson OB; Knudsen GM
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):623-31. PubMed ID: 11976800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.